S.C. Ropharma S.A (RPH) Fair Value & Analysis
Healthcare · RO · Market cap 102M RON
Fair value as of: Jun 24, 2026
From 17 valuation models · updated 8 days ago
Price vs Fair Value (12 months)
12‑month range 0.1580 RON – 0.2260 RON · fair‑value band 0.5500 RON – 1.70 RON · the 0.2000 RON price screens below the 0.9400 RON fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
S.C. Ropharma S.A (RPH) currently trades at 0.2000 RON, while our model-based Fair Value estimate is 0.9400 RON — implying the stock looks roughly 370.0% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, S.C. Ropharma S.A generated revenue of 1.5B RON at a net margin of 0.1%. Revenue grew 20.1% year over year. It earns a return on equity of 2.6%. Net debt stands at 47.9M RON. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
S.C. Ropharma S.A. operates a chain of pharmacies in Romania. The company distributes over-the-counter medications, food supplements, cosmetics, perfumes, medical devices, dermato-cosmetics, para pharmaceuticals, and other medicines through pharmaceutical warehouses. It also offers cardiovascular, dermatological, digestive, ophthalmological, osteoarticular, respiratory, urogenital, and diabetes medicines. In addition, the company provides supplements for immunity, antioxidants, vitamins and mineral medicines, and food and supplements for children, pregnancy, and breastfeeding medicines; and cosmetics for children, diapers, napkins, and protection against insects. Further, it offers body, hair, and skin care products; oral hygiene, solar protection, hand and foot care, and anti-insect products. Additionally, the company provides fertility, condoms, pregnancy and ovulation tests, and reproductive tonics; and medical equipment, protective glasses, and waterproof plasters. The company …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
S.C. Ropharma S.A reported revenue of 1.2B RON in FY2025 versus 718M RON in FY2021, a compound +13.5%/yr. Reported net income was −1.7M RON in FY2025.
Is RPH fairly valued? → Check now
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIF | $5.85 | $7.13 | +22% |
| 6618 6618 | HK$34.16 | HK$33.08 | -3% |
| Alibaba Health Information Technology Limited ALBBY | $8.27 | $6.61 | -20% |
| 0241 0241 | HK$3.08 | HK$2.04 | -34% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is S.C. Ropharma S.A (RPH) undervalued?
What is the fair value of RPH?
What is the quality score of RPH?
What is the revenue of S.C. Ropharma S.A (RPH)?
What is the net profit margin of RPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.